Literature DB >> 16198161

Characterisation of kinase-selective inhibitors by chemical proteomics.

Henrik Daub1.   

Abstract

Low-molecular-weight inhibitors of protein kinases are extensively used as research tools in signal transduction analysis and constitute a rapidly growing class of therapeutics for targeted intervention in human diseases. To determine how kinase-selective drugs interfere with cellular physiology on the molecular level, experimental strategies relying on the affinity capture of cellular targets in combination with protein identification by mass spectrometry have been established for a variety of kinase inhibitors. Importantly, these chemical proteomic methods permit the direct analysis of kinase inhibitor selectivity in biological systems and have led to new insights into the cellular modes of action of kinase-selective small molecule antagonists.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16198161     DOI: 10.1016/j.bbapap.2005.07.028

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Large-scale proteomics analysis of the human kinome.

Authors:  Felix S Oppermann; Florian Gnad; Jesper V Olsen; Renate Hornberger; Zoltán Greff; György Kéri; Matthias Mann; Henrik Daub
Journal:  Mol Cell Proteomics       Date:  2009-04-15       Impact factor: 5.911

2.  Recent advances in chemical proteomics: exploring the post-translational proteome.

Authors:  Edward W Tate
Journal:  J Chem Biol       Date:  2008-05-09

3.  Proteomics strategy for quantitative protein interaction profiling in cell extracts.

Authors:  Kirti Sharma; Christoph Weber; Michaela Bairlein; Zoltán Greff; György Kéri; Jürgen Cox; Jesper V Olsen; Henrik Daub
Journal:  Nat Methods       Date:  2009-09-13       Impact factor: 28.547

Review 4.  Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling.

Authors:  Bin Fang; Eric B Haura; Keiran S Smalley; Steven A Eschrich; John M Koomen
Journal:  Biochem Pharmacol       Date:  2010-03-31       Impact factor: 5.858

5.  Computational design of targeted inhibitors of polo-like kinase 1 (plk1).

Authors:  Krupa S Jani; D S Dalafave
Journal:  Bioinform Biol Insights       Date:  2012-02-20

6.  Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics.

Authors:  Cuiping Pan; Jesper V Olsen; Henrik Daub; Matthias Mann
Journal:  Mol Cell Proteomics       Date:  2009-08-03       Impact factor: 5.911

7.  The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.

Authors:  Oliver Hantschel; Uwe Rix; Uwe Schmidt; Tilmann Bürckstümmer; Michael Kneidinger; Gregor Schütze; Jacques Colinge; Keiryn L Bennett; Wilfried Ellmeier; Peter Valent; Giulio Superti-Furga
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-07       Impact factor: 11.205

8.  A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL.

Authors:  Uwe Rix; Jacques Colinge; Katharina Blatt; Manuela Gridling; Lily L Remsing Rix; Katja Parapatics; Sabine Cerny-Reiterer; Thomas R Burkard; Ulrich Jäger; Junia V Melo; Keiryn L Bennett; Peter Valent; Giulio Superti-Furga
Journal:  PLoS One       Date:  2013-10-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.